

## **Remarks**

### **Amendments to the Specification**

Applicants have revised the specification to update the priority data and to correct typographical errors. On page 8, lines 9-17, the specification has been amended to correct the sequence for human oxyntomodulin (OXM) (page 8, lines 14-17), which has an Arg and not a Lys residue at position 33. The corrected sequence has been renamed SEQ ID NO: 9 in the specification and is included in the corrected version of the Sequence Listing. The specification has also been amended to state that the bovine OXM sequence is not the same as the human, rat and hamster sequences. The specification has also been amended on page 26, lines 24-25, to state that the OXM used in the experiments was not human OXM.

None of these amendments constitute new matter. Both the correct sequence for human oxyntomodulin and the relationships between bovine, human, rat and hamster oxyntomodulin sequences were known prior to filing of this application. Enclosed are copies of the Swiss-Prot database entries for human, bovine, rat and hamster OXM to prove the sequences were known.

### **Amendments to the Claims**

Claims 1-37 have been cancelled. New claims 38-61 correspond to the claims as originally filed in the International Application, as demonstrated below.

#### **New    Original**

38      28

39      34

40      35

International Application No.: PCT/GB2004/000017  
International Filing Date: January 12, 2004  
**PRELIMINARY AMENDMENT**  
Express Mail Label No.: EV 487329266 US  
Date of Deposit: July 7, 2005

41	29
42	30/31/32
43	22
44	23
45	13/26
46	14/26
47	37/27
48	1/2/3/6/7/8 + 16
49	4
50	5
51	10
52	11
53	12
54	17
55	18/19/20
56	22
57	23
58	13
59	14
60	15
61	21

International Application No.: PCT/GB2004/000017  
International Filing Date: January 12, 2004  
**PRELIMINARY AMENDMENT**  
Express Mail Label No.: EV 487329266 US  
Date of Deposit: July 7, 2005

**Declaration under 37 C.F.R. § 1.821(f)**

I declare that the material on the enclosed diskette is identical to the enclosed paper copy of the Sequence Listing, that the Sequence Listing does not add new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

No new matter has been added by way of this Preliminary Amendment, entry of which is respectfully requested.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Date: July 7, 2005

PABST PATENT GROUP LLP  
400 Colony Square, Suite 1200  
1201 Peachtree Street  
Atlanta, Georgia 30361  
(404) 879-2151 (Telephone)  
(404) 879-2160 (Fax)